Peptide
Melanotan 1
SaveA linear alpha-MSH analog (afamelanotide) that stimulates melanogenesis. EMA-approved as Scenesse for erythropoietic protoporphyria (EPP).
Quick verdict
One of the few peptides in this list with full regulatory approval for a specific condition (EPP). More selective and safer than Melanotan II.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
EMA-approved for EPP based on RCT data. Does not cross-activate MC1R/MC4R receptors as broadly as MT-II. Additional research for vitiligo and photoprotection.
Benefits
- EMA-approved for erythropoietic protoporphyria
- Increased pain-free sun exposure in EPP patients
- More selective melanocortin receptor profile than MT-II
Dosage notes
Scenesse: 16 mg subcutaneous implant every 2 months (prescribed for EPP only).
Side effects
- Nausea
- Headache
- Skin darkening
- Implant-site reactions
- Rare mole changes requiring monitoring
Who should be cautious
Prescription-only for EPP. Implant formulation. Dark-skinned individuals may develop hyperpigmentation.
What this page cannot tell you
Approved only for EPP. Cosmetic tanning use is off-label and not evaluated for safety in that context.
Write a review
Sign in to write a review.